Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | SLC6A1 | P30531 | 2/20 | 0.33 |
| ▸ | SLC6A11 | P48066 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | SLC6A13 | Q9NSD5 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6356425 | 1.00 | CYP1A2 (0.41) | CYP1A2SLC6A1SLC6A11TSHRLMNA | |
| SCHEMBL6355889 | 1.00 | CYP1A2 (0.41) | CYP1A2SLC6A1SLC6A11TSHRLMNA | |
| SCHEMBL6357549 | 0.90 | CYP1A2 (0.33) | CYP1A2SLC6A1SLC6A11TSHRLMNA | |
| SCHEMBL6353216 | 0.80 | GRM2 (0.30) | CYP1A2 | |
| SCHEMBL6353304 | 0.78 | SLC6A1 (0.35) | SLC6A1SLC6A11TSHRLMNASMN1; SMN2 | |
| SCHEMBL6353299 | 0.78 | SLC6A1 (0.35) | SLC6A1SLC6A11TSHRLMNASMN1; SMN2 | |
| SCHEMBL6355747 | 0.78 | SLC6A1 (0.35) | SLC6A1SLC6A11TSHRLMNASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL3832160 | 0.76 | SLC6A1 (0.34) | SLC6A1SLC6A11TSHRLMNASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL6357581 | 0.76 | SLC6A1 (0.34) | SLC6A1SLC6A11TSHRLMNASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL3832164 | 0.76 | SLC6A1 (0.34) | SLC6A1SLC6A11TSHRLMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050250800-A1 | Conformationally constrained compounds as pharmaceutical agents | BRYANS JUSTIN S | 2005-11-10 | — | — | US | claimed |
| US-20030119858-A1 | Conformationally constrained compounds as pharmaceutical agents | BRYANS JUSTIN STEPHEN (GB) | 2003-06-26 | — | — | US | claimed |
| US-20020019540-A1 | Conformationally constrained compounds as pharmaceutical agents | BRYANS JUSTIN STEPHEN (GB) | 2002-02-14 | — | — | US | claimed |
| US-6316638-B1 | FOR THERAPY OF EPILEPSY, FAINTNESS ATTACKS, HYPOKINESIA, CRANIAL DISORDERS, NEURODEGENERATIVE DISORDERS, DEPRESSION, ANXIETY, PANIC, PAIN, AND NEUROPATHOLOGICAL DISORDERS | WARNER-LAMBERT COMPANY | 2001-11-13 | — | — | US | claimed |
| EP-1082306-A1 | CONFORMATIONALLY CONSTRAINED AMINO ACID COMPOUNDS HAVING AFFINITY FOR THE ALPHA2DELTA SUBUNIT OF A CALCIUM CHANNEL | WARNER-LAMBERT COMPANY (US) | 2001-03-14 | — | — | EP | claimed |
| WO-1999061424-A1 | CONFORMATIONALLY CONSTRAINED AMINO ACID COMPOUNDS HAVING AFFINITY FOR THE ALPHA2DELTA SUBUNIT OF A CALCIUM CHANNEL | WARNER-LAMBERT COMPANY (US) | 1999-12-02 | — | — | WO | claimed |
| US-20050250800-A1 | Conformationally constrained compounds as pharmaceutical agents | BRYANS JUSTIN S | 2005-11-10 | — | — | US | disclosed |
| US-20030119858-A1 | Conformationally constrained compounds as pharmaceutical agents | BRYANS JUSTIN STEPHEN (GB) | 2003-06-26 | — | — | US | disclosed |
| US-6489352-B2 | ANTIEPILEPTIC AGENTS; NERVOUS SYSTEM DISORDERS | WARNER-LAMBERT COMPANY | 2002-12-03 | — | — | US | disclosed |
| US-20020019540-A1 | Conformationally constrained compounds as pharmaceutical agents | BRYANS JUSTIN STEPHEN (GB) | 2002-02-14 | — | — | US | disclosed |
| US-6316638-B1 | FOR THERAPY OF EPILEPSY, FAINTNESS ATTACKS, HYPOKINESIA, CRANIAL DISORDERS, NEURODEGENERATIVE DISORDERS, DEPRESSION, ANXIETY, PANIC, PAIN, AND NEUROPATHOLOGICAL DISORDERS | WARNER-LAMBERT COMPANY | 2001-11-13 | — | — | US | disclosed |
| EP-1082306-A1 | CONFORMATIONALLY CONSTRAINED AMINO ACID COMPOUNDS HAVING AFFINITY FOR THE ALPHA2DELTA SUBUNIT OF A CALCIUM CHANNEL | WARNER-LAMBERT COMPANY (US) | 2001-03-14 | — | — | EP | disclosed |
| WO-1999061424-A1 | CONFORMATIONALLY CONSTRAINED AMINO ACID COMPOUNDS HAVING AFFINITY FOR THE ALPHA2DELTA SUBUNIT OF A CALCIUM CHANNEL | WARNER-LAMBERT COMPANY (US) | 1999-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050250800-A1 | Conformationally constrained compounds as pharmaceutical agents | PYGB, GABRA6, GABRA2 | CYP1A2 2155/4885SLC6A1 45/4885SLC6A11 54/4885 |
| US-20020019540-A1 | Conformationally constrained compounds as pharmaceutical agents | PYGB, SLC18A1, CDR2 | CYP1A2 1699/4885SLC6A1 47/4885SLC6A11 110/4885 |
| US-20030119858-A1 | Conformationally constrained compounds as pharmaceutical agents | PYGB, SLC18A1, CDR2 | CYP1A2 1699/4885SLC6A1 47/4885SLC6A11 110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.